Each sector has its own evidence rules, authorities and unwritten conventions. We bring sector-specific judgement not a generalist's checklist.


REACH and UK REACH registrants navigating dossier evaluation, substance evaluation, and the rising bar for endocrine, PMT and PBT assessment. We help you anticipate the next regulatory question not react to it.

Active substance approvals and renewals under EU BPR. Endocrine disruptor assessment under EFSA/ECHA guidance, technical equivalence, and impurity relevancy reasoning the scientific work that holds renewal dossiers together under peer review.

CPSRs signed by qualified Safety Assessors. Ingredient assessments to SCCS standard, NAM-based weight-of-evidence reasoning, and Responsible Person support across EU and UK markets.

Impurity qualification under ICH M7, nitrosamine risk assessment and CPCA reasoning, PDE/OEL derivation, and E&L safety qualification for medicinal products. ISO 10993-aligned biological evaluation and toxicological risk assessment for medical devices aligned with the questions EU/MHRA and US FDA reviewers actually ask.